Domestic pharmaceutical firms' strategic alliances with bioventure firms up

In his recent report, a researcher Kim Seok-kwan, Industry Renovation Research Unit of Science & Technology Policy Institute, says that under the circumstances where R&D outlays of the domestic pharmaceutical firms has been in downward trends, their strategic alliances with biotechnology firms may be an efficient tool to acquire the latter's inexpensive renovation and such relationship should b...